<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555644</url>
  </required_header>
  <id_info>
    <org_study_id>16016</org_study_id>
    <secondary_id>I4D-MC-JTJI</secondary_id>
    <secondary_id>2015-001215-12</secondary_id>
    <nct_id>NCT02555644</nct_id>
  </id_info>
  <brief_title>A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer</brief_title>
  <official_title>A Phase 1b Trial of LY2606368 in Combination With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the safety of prexasertib in combination&#xD;
      with other anti-cancer drugs (cisplatin or cetuximab) and radiation therapy in participants&#xD;
      with locally advanced head and neck cancer. The study has two parts (A and B). Participants&#xD;
      will only enroll in one part.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of Parts A and B of this study is to determine a recommended dose level&#xD;
      of prexasertib (an inhibitor of checkpoint kinase 1[Chk-1]) in combination with cisplatin and&#xD;
      radiation therapy (Part A) or cetuximab and radiation therapy (Part B) in participants with&#xD;
      locally advanced head and neck cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2016</start_date>
  <completion_date type="Actual">January 14, 2019</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Maximum Tolerated Dose of Prexasertib in Combination with Cisplatin and Radiation Therapy</measure>
    <time_frame>First Dose through Last Dose (Estimated up to 7 Weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Maximum Tolerated Dose of Prexasertib in Combination with Cetuximab and Radiation Therapy</measure>
    <time_frame>First Dose through Last Dose (Estimated up to 8 Weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration of Prexasertib, Cisplatin and Cetuximab</measure>
    <time_frame>First Dose through Last Dose (Estimated up to 8 Weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Curve (AUC) of Prexasertib</measure>
    <time_frame>First Dose through Last Dose (Estimated up to 8 Weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Control Rate</measure>
    <time_frame>Baseline through One Year (Estimated as up to 52 Weeks) or Death from Any Cause</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Prexasertib + Cisplatin + Radiation Therapy (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prexasertib administered intravenously (IV) every 14 days over an approximately 49-day treatment period.&#xD;
Cisplatin administered IV every 7 days over an approximately 49-day treatment period.&#xD;
Intensity modulated radiation therapy administered 5 days per week over an approximately 49-day treatment period.&#xD;
Participants may remain on treatment until completion of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prexasertib + Cetuximab + Radiation Therapy (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prexasertib administered IV every 14 days over an approximately 56-day treatment period.&#xD;
Cetuximab administered IV every 7 days over an approximately 56-day treatment period.&#xD;
Intensity modulated radiation therapy administered 5 days per week over an approximately 56-day treatment period (starting at Week 2).&#xD;
Participants may remain on treatment until completion of the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prexasertib</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Prexasertib + Cetuximab + Radiation Therapy (Part B)</arm_group_label>
    <arm_group_label>Prexasertib + Cisplatin + Radiation Therapy (Part A)</arm_group_label>
    <other_name>LY2606368</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Prexasertib + Cisplatin + Radiation Therapy (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Prexasertib + Cetuximab + Radiation Therapy (Part B)</arm_group_label>
    <other_name>Erbitux</other_name>
    <other_name>LY2939777</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity Modulated Radiation Therapy</intervention_name>
    <arm_group_label>Prexasertib + Cetuximab + Radiation Therapy (Part B)</arm_group_label>
    <arm_group_label>Prexasertib + Cisplatin + Radiation Therapy (Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be able to comply with the treatment plan and follow-up schedule&#xD;
&#xD;
          -  Must have diagnosis of head and neck squamous cell carcinoma of the oropharynx&#xD;
             (tonsil, base of tongue, soft palate, or oropharyngeal walls), hypopharynx, or larynx&#xD;
&#xD;
          -  Have adequate organ function&#xD;
&#xD;
          -  If participant is of reproductive potential, must agree to use medically approved&#xD;
             contraceptive precautions during the study and for six months following the last dose&#xD;
             of study drug&#xD;
&#xD;
          -  If the participant is a female of childbearing potential, must have had a negative&#xD;
             serum or urine pregnancy test within 14 days of the first dose of study drug and must&#xD;
             not be breast feeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Must not have taken an unapproved drug as treatment for any indication within the last&#xD;
             28 days prior to starting study treatment&#xD;
&#xD;
          -  Must not have received any of the following prior therapies or treatments: systemic&#xD;
             therapy for the study cancer, radiation therapy to the head and neck region, or&#xD;
             curative-intent surgery in the head and neck region&#xD;
&#xD;
          -  Have evidence of a distant metastatic disease&#xD;
&#xD;
          -  Must not have an active symptomatic fungal, bacterial or viral infection, including&#xD;
             human immunodeficiency virus (HIV) or Hepatitis A, B, or C&#xD;
&#xD;
          -  Must not have a serious heart condition, such as congestive heart failure, unstable&#xD;
             angina pectoris, or heart attack within the last three months&#xD;
&#xD;
          -  Must not have a family history of long corrected QT interval (QTc) syndrome&#xD;
&#xD;
          -  Must not have known allergic reaction against any of the components of the study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrialguide.com/EN/studies/cancer/jtji</url>
    <description>Click here for more information about this study: A Study of Prexasertib (LY2606368) with Chemotherapy and Radiation in Participants with Head and Neck Cancer</description>
  </link>
  <verification_date>February 1, 2019</verification_date>
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

